What to Expect When Your Patient Is Starting Immune Checkpoint Inhibitor–Based Therapy: Slides

Download these slides for an expert survey of key safety and efficacy considerations for multidisciplinary healthcare providers caring for patients starting immune checkpoint inhibitors.
Marianne Davies, DNP, CNS, ACNP-BC, AOCNP
Format: Microsoft PowerPoint (.ppt)
File Size: 2.76 MB
Released: March 23, 2021


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Bristol-Myers Squibb
Merck Sharp & Dohme Corp.

Related Content

GeparNUEVO survival outcomes with durvalumab + neoadjuvant chemo in early triple-negative breast cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: June 9, 2021

Phase II study of niraparib with/without dostarlimab shows a CBR of 31.8% vs 20.0% with monotherapy in recurrent EC from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 8, 2021

Short expert video on the management of key toxicities associated with CAR T-cell therapy, including CRS and ICANS, from Clinical Care Options (CCO)

Michael R. Bishop, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: May 27, 2021 Expired: May 26, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.